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Background: HIV infection is an independent risk factor for pulmonary arterial hypertension (PAH), but the underlying mechanisms remain 
unknown. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase. As NO inhibits thrombosis, 
inflammation, and smooth muscle proliferation, key mechanisms in PAH, loss of NO due to elevated ADMA might lead to PAH. The purpose of this 
study was to evaluate the association between ADMA and PAH in the setting of HIV infection.
Methods: We measured ADMA using high-performance liquid chromatography in HIV-infected individuals. Pulmonary artery systolic pressure (PASP) 
was assessed in all subjects with Doppler echocardiography and confirmed by right heart catheterization in individuals with PASP > 30 mmHg. We 
used Poisson regression with a robust variance estimator to determine the relative risk for factors associated with PAH (PASP > 30 mmHg or mean 
PAP > 25 mmHg).
Results: We studied 162 HIV-infected individuals; with median age 50 years, 84% male, 73% on antiretroviral therapy, 75% with undetectable HIV 
RNA levels, and median CD4+ count 576 cells/mm3. The median ADMA was 0.48 μmol/l (IQR 0.43-0.54). The unadjusted rank correlation between 
ADMA and PASP was r=0.14 (p=0.074). In unadjusted analysis, ADMA was associated with higher prevalence of PASP > 30 mmHg [prevalence 
ratio (PR) = 1.23, 95% CI 1.01-1.51, p=0.044]. The association was slightly attenuated after multivariable adjustment for traditional pulmonary 
hypertension and HIV-specific risk factors (PR=1.22, 95% CI 0.99-1.51, p=0.063). Sixty seven patients underwent right heart catheterization, and 
the unadjusted rank correlation between ADMA and PAP was r=0.21 (p=0.096). In unadjusted analysis, ADMA was associated with PAP > 25 mmHg 
(PR=1.30, 95% CI 1.03-1.63, p=0.026). The association remained significant after multivariable adjustment (PR=1.28, 95% CI 1.00-1.64, p=0.046).
Conclusions: High ADMA levels are associated with PAH among HIV-infected individuals. Our findings suggest that endothelial dysfunction 
secondary to elevated ADMA leading to a loss of nitric oxide may represent a novel mechanism for HIV-associated PAH.
